End-of-life communication in advanced cancer: international trends (2009–2014)

Mariëtte N Verkissen,¹ Yolanda W H Penders ⁽¹⁾,² Bregje D Onwuteaka-Philipsen,³ Sarah Moreels,⁴ Gé A Donker,⁵ Tomás Vega Alonso,⁶ Lieve Van den Block,¹ Luc Deliens^{1,7}

For numbered affiliations see end of article.

Correspondence to

Mariëtte N Verkissen, Department of Family Medicine and Chronic Care, End-of-Life Care Research Group, Vrije Universiteit Brussel (VUB) & Ghent University, Brussels, Belgium;

mariette.verkissen@vub.be

Received 12 August 2019 Revised 17 January 2020 Accepted 9 March 2020

Check for updates

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Verkissen MN, Penders YWH, Onwuteaka-Philipsen BD, et al. BMJ Supportive & Palliative Care Epub ahead of print: [please include Day Month Year]. doi:10.1136/ bmjspcare-2019-001999

ABSTRACT

Objective To examine trends in end-of-life communication with people with cancer in general practice.

Methods Mortality follow-back survey among general practitioners (GPs) in representative epidemiological surveillance networks in Belgium (BE), the Netherlands (NL) and Spain (ES) in 2009–2010 (ES: 2010–2011) and 2013–2014. Using a standardised form, GPs registered all deceased adult patients in their practice and reported for five end-of-life care topics whether they had been discussed with the patient. Non-sudden cancer deaths were included (n=2306; BE: 1233; NL: 729; ES: 344).

Results A statistically significant increase was found between 2009/2010 and 2014 in the prevalence of communication about diagnosis (from 84% to 94%) and options for end-oflife care (from 73% to 90%) in BE, and in GPs' awareness of patients' preferences for medical treatment and a proxy decision-maker in BE (from 41% and 20% up to 53% and 28%) and the NL (from 62% and 32% up to 70% and 52%). Communication about options for end-of-life care and psychosocial problems decreased in the NL (from 88% and 91% down to 73%) and ES (from 76% and 77% down to 26% and 39%). **Conclusion** Considerable change in GP-patient communication seems possible in a relatively short time span, but communication cannot be assumed to increase over time. Increasing specialisation of care and task differentiation may lead to new roles in communication for healthcare providers in primary and secondary care. Improved information sharing between GPs and other healthcare providers may be necessary to ensure that patients have the chance to discuss important end-of-life topics.

INTRODUCTION

Despite the progress made over the past decade in prevention and treatment,

cancer remains the second-leading cause of death in the European Union, accounting for more than one quarter of all deaths.¹ With an ageing population that continues to grow, it is anticipated that the cancer incidence and mortality will rise further in the coming years. As a result, more people with cancer will require palliative care.²

High-quality palliative care requires that physicians engage in meaningful patient-centred communication,³⁴ which has several aims including fostering an interpersonal relationship, exchanging appropriate information and responding to uncertainty and emotions.⁵ Effective physician-patient communication has been related to favourable patient outcomes, such as better understanding of the illness, care and treatment options,⁶ adherence to treatment⁵⁷ and satisfaction with end-of-life care.^{5 8} Inadequate communication is associated with adverse outcomes, including emotional distress and worsening of symptoms.⁹

Communication between healthcare providers and patients in oncology has often been shown to be infrequent and suboptimal.¹⁰ ¹¹ Possible barriers for physicians to engage in effective endof-life communication include a natural reluctance to raise this subject, lacking knowledge or training in this area and inadequate structural support for advance care planning (ACP).^{12¹³} In Europe, patient-centred communication and ACP have received increasing policy attention over the last years, with efforts made in many countries to implement training, programmes and guidelines for palliative care.

In light of these developments, this study aims to examine trends in endof-life communication between general

practitioners (GPs) and people with advanced cancer in three European countries-Belgium (BE), the Netherlands (NL) and Spain (ES)-from 2009 to 2014, based on data collected by GP networks. BE, the NL and ES are all considered to be at the highest level of palliative care development, that is, advanced integration into mainstream service provision.¹⁴ Since 2000, efforts have been made in BE and the NL to increase opportunities for palliative care training, as well as implementing programmes and constructing guidelines to improve end-of-life communication practices.¹⁴⁻¹⁶ In ES, palliative care has continued to develop and has been integrated in educational programmes,¹⁴ but without such a specific focus on ACP or communication. However, it is likely that different cultural traditions, attitudes towards the end of life,¹⁷ healthcare systems, policies and available resources¹⁴ ¹⁸ affect end-of-life communication practices. Cross-country comparative studies focusing on aspects of end-of-life communication among individuals with cancer are scarce, although previous research has indicated that European countries vary substantially with regard to the process and content of physicians' discussions with terminally ill patients.¹⁹

Because GPs play a crucial role in the coordination and delivery of palliative care, they are well placed to initiate end-of-life conversations with their patients. General practice is relatively easily accessible in the studied countries. In the NL and ES, GPs serve as gatekeepers for healthcare delivery, they act as referral and care coordinators.^{20 21} Patients are registered with a specific GP and do not have direct access to secondary or specialist care. In BE, GPs have a central coordinating role in patient care but do not have a gatekeeper function, but GPs are the ones who contact palliative home care teams when necessary.²¹

Our study explores whether conversations about topics related to end-of-life care with people with cancer in primary care have become more frequent between 2009 and 2014. The specific research questions are:

- 1. Did the percentages of people with cancer with whom end-of-life topics (diagnosis, options for end-of-life care, psychological or social problems, preference for medical treatment in the final phase of life, preference for a proxy decision-maker) were discussed change between 2009 and 2014 in BE, the NL and ES, and in what direction?
- 2. Were there differences in the time trends in GP-patient end-of-life communication with respect to age, gender, longest place of residence and place of death?

METHODS

Study design

This study uses data from BE, the NL and ES (Castile and León and Valencian Community regions) collected as part of the European Sentinel Network Monitoring End-of-Life Care (EURO SENTIMELC) study, an ongoing mortality follow-back study designed to retrospectively monitor end-of-life care in population-based samples of deaths in different countries.²¹ Data were collected through existing representative GP Sentinel Networks, epidemiological surveillance networks consisting of GP practices or community-based physicians who voluntarily and continuously monitor health problems occurring in the population. In each country, GPs were selected to form a representative national sample of the total GP population and invited to participate in the networks by national public health and/or research institutes. By comparing the characteristics of GPs in the Sentinel Networks to the general population of GPs—such as age, gender and geographical distribution-the responsible institutes ensure continued representativity of the networks. Patient data were anonymised by the GPs; GP data were anonymised by the responsible institute during data cleaning. Participating GPs provided weekly reports on every adult patient in their practice who had died during the past week as part of a larger public health questionnaire. In the NL, elderly care physicians who are responsible for the care of long-term care facility residents are not part of the GP Sentinel Network; this exact physician role does not exist in BE and ES. Data used in this study were collected in 2009, 2010, 2013 and 2014 in BE and the NL, and in 2010, 2011, 2013 and 2014 in ES. More details on the data collection and study design are described elsewhere.²¹

Study population

We included all people registered by the participating GP practices who died of cancer (according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) code), for a total of n=2627. People whose death was classified by the GPs as 'sudden and totally unexpected' and those for whom this information was missing were excluded, leaving a sample that was eligible for palliative care (n=2306).

Questionnaire

Using a standardised registration form consisting of structured and closed-ended items, GPs collected demographic characteristics (age at death, gender, longest place of residence in the last year of life, place of death), cancer type (coded according to ICD-10) and whether or not death was sudden and unexpected. Additionally, the following questions were asked regarding end-of-life communication:

1. Were the following topics addressed during your conversations with the patient?

Diagnosis—the answer options were 'yes' or 'no'. Options for end-of-life care—the answer options were 'yes' or 'no'. In 2009–2010, this item was phrased as 'options for palliative care', in 2013–2014 as 'options in terms of end-of-life care', to be more in line with quality indicator measurement tools developed for general palliative care. $^{\rm 22}$

Psychological or social problems—the answer options were 'yes' or 'no'. In 2009–2010, these concepts were measured by two separate items which were combined for this analysis.

- 2. Did the patient ever express wishes about a medical treatment that he/she would or would not want in the final phase of life? The answer options were 'yes', 'no' or 'don't know'.
- 3. Did the patient ever express a wish about who was to make decisions regarding medical treatments or activities in his/her place, in the event he/she would no longer be able to speak for him/herself? The answer options (more than one possible) were 'yes, in writing', 'yes, verbally', 'no' or 'don't know'.

Statistical analyses

If the GP indicated 'don't know' as an answer to question 2 or 3, this was coded as 'no'.

Pearson's X² tests, Fisher's exact tests or analysis of variance were performed to test for differences in patient characteristics (age at death, gender, cancer type, longest place of residence in the last year of life, place of death) between years. Bivariate Mantel-Haenszel tests were calculated to detect linear trends in the proportion of people with cancer with whom any of the five studied end-of-life care topics were discussed between 2009 and 2014. Multivariable trend analyses controlling for age, gender, cancer type, longest place of residence in the last year of life and place of death were used to test for linear trends in proportions through the SPSS UNIANOVA procedure, specifying a polynomial contrast for the variable year. A significant result on this test provides strong evidence for a linear relationship between year and topic discussed, as the number of patients with whom a topic was discussed in later years was significantly above what might be expected if there was no relationship between the variables. A power analysis was conducted for each variable in each country, assuming a medium effect size, showing that power was above 95% for all variables in BE, preferences for medical treatment and a proxy decision-maker in the NL and diagnosis in ES. Power was between 68% and 78% for the remaining variables in the NL, and below 55% for the remaining variables in ES, suggesting that the trend analysis for these variables may be underpowered. Statistical significance was set at p < 0.05. All analyses were performed using IBM SPSS Statistics V.24.0.

RESULTS

Characteristics of the study population

A total of 2306 cancer decedents were included (BE=1233; NL=729; ES=344; table 1). The median age at death was between 73 and 78 years. In general, the most common cause of death was lung cancer (BE: 21%-25%; NL: 22%-29%; ES:

17%–20%). The majority of people lived at home in the last year of life (BE: 81%–88%; NL: 88%–91%; ES: 92%–97%) and in general, home was the most common place of death (BE: 31%–38%; NL: 54%–62%; ES: 41%–50%). In ES, the percentage of women was considerably lower than the percentage of men (30%–34% across years). Additional data analysis showed that this relatively large gender imbalance was present only for those who died of cancer, regardless of whether death was 'sudden and totally unexpected', possibly because in ES, 60% of new cancers are diagnosed in men.²³

Trends in the proportion of people with whom end-of-life care topics were discussed

BE was the only country to see a significant increase in the percentage of people with whom their diagnosis was discussed between 2009 and 2014 (from 84% to 94%, p<0.01) (table 2; figure 1). In multivariable regression models controlling for age, gender, cancer type, longest place of residence in the last year of life and place of death, this increase was significant for all age groups, both genders, those who lived at home and in a long-term facility in the last year of life, and those who died at home, in a hospital and in a long-term care facility (table 3).

The percentage of people with whom options for end-of-life care were discussed showed an increasing trend in BE between 2009 and 2014 (from 73%) to 90%, p<0.001), but decreased significantly in the NL between 2009 and 2014 (from 88% to 73%, p<0.001) and in ES between 2010 and 2014 (from 76% to 26%, p<0.001) (table 2; figure 1). In multivariable regression, the increase in BE was significant for all age groups and both genders, for those who lived at home in the last year of life, and for those who died at home, in a hospital and in a palliative care unit or hospice (table 3). In the NL, the decreasing trend was significant for those aged 65-84 and 85+, both genders, those who lived at home in the last year of life, and those who died at home and in a palliative care unit or hospice. In ES, the decrease was significant for those aged 65-84, both genders, those who lived at home in the last year of life and those who died at home.

The percentage of people with whom psychological or social problems were discussed decreased significantly over time in both the NL (from 91% to 73%, p<0.001) and ES (from 77% to 39%, p<0.001). In multivariable regression, this decrease was significant in the NL for all age groups, both genders, those who lived at home and in a long-term care facility during the last year of life and for all place of death groups (table 3). In ES, the decrease was significant for those aged 18–64, females, those who lived at home in the last year of life and those who died at home. While overall no decreasing trend in communication about

lable 1 Charac	teristics of the	e study popul	ation: people	with cancer	who died	non-sudden	y in Belgium,	the Netherlé	ands and Spai	n, 2009–	-2014 (n=23((QC			
	Belgium					The Netherlands					Spain				
	2009	2010	2013	2014		2009	2010	2013	2014		2010	2011	2013	2014	
	n=303	n=292	n=336	n=302		n=157	n=189	n=190	n=193		n=80	n=86	n=88	n=90	
	(%) N	(%) N	(%) N	(%) N	P value*	(%) N	(%) N	(%) N	(%) N	P value*	(%) N	(%) N	(%) N	(%) N	P value*
Age at death (years), median (95% CI)	74 (72 to 76)	75 (73 to 77)	77 (75 to 79)	77 (74 to 79)	0.02	73 (70 to 75)	73 (72 to 76)	73 (71 to 75)	75 (72 to 76)	0.23	77.5 (73 to 81)	77 (74 to 81)	78 (77 to 83)	76.5 (72 to 79)	0.18
Gender, female	129 (43)	138 (47)	160 (48)	138 (46)	0.58	83 (53)	76 (41)	89 (47)	93 (48)	0.15	24 (30)	28 (33)	30 (34)	31 (34)	0.93
Primary cancer site															
Lung	76 (25)	72 (25)	72 (21)	70 (23)	0.69	34 (22)	46 (27)	40 (24)	52 (29)	0.41	15 (20)	15 (19)	14 (17)	16 (18)	0.96
Colorectal	33 (11)	36 (12)	47 (14)	42 (14)	0.61	12 (8)	28 (16)	23 (14)	21 (12)	0.12	21 (28)	12 (15)	7 (8)	3 (3)	<0.001
Breast	22 (7)	29 (10)	37 (11)	19 (6)	0.12	26 (17)	8 (5)	18 (11)	11 (6)	<0.01	5 (7)	5 (6)	13 (15)	15 (17)	0.05
Prostate	10 (3)	15 (5)	26 (8)	20 (7)	0.09	11(7)	13 (8)	14 (8)	6 (3)	0.25	8 (11)	9 (11)	5 (6)	3 (3)	0.18
Other	162 (54)	140 (48)	154 (46)	151 (50)	0.26	74 (47)	78 (45)	75 (44)	89 (50)	0.73	27 (36)	40 (49)	46 (54)	50 (58)	0.03
Longest place of reside	ence in last year†														
Home	261 (87)	255 (88)	288 (86)	243 (81)	0.10	143 (91)	166 (90)	167 (88)	173 (91)	0.84	73 (92)	79 (94)	78 (92)	86 (97)	0.55
Long-term care facility	34 (11)	31 (11)	38 (11)	51 (17)	0.07	14 (9)	18 (10)	19 (10)	13 (7)	0.68	6 (8)	2 (2)	5 (6)	2 (2)	0.26
Place of death†															
Home	94 (31)	102 (35)	126 (38)	95 (32)	0.28	84 (54)	110 (58)	114 (60)	118 (62)	0.45	39 (49)	42 (50)	30 (41)	37 (41)	0.49
Hospital	103 (34)	98 (34)	95 (28)	90 (30)	0.30	28 (18)	30 (16)	31 (16)	33 (17)	0.96	23 (29)	27 (32)	23 (31)	24 (27)	0.86
PCU/hospice	65 (22)	57 (20)	62 (19)	45 (15)	0.20	27 (17)	27 (14)	23 (12)	23 (12)	0.47	10 (13)	13 (16)	17 (23)	24 (27)	0.08
Long-term care facility	38 (13)	33 (11)	51 (15)	68 (23)	<0.01	17 (11)	22 (12)	21 (11)	15 (8)	0.62	8 (10)	2 (2)	4 (5)	5 (6)	0.23
Missing data <1.5% for all ve	ıriables.														
*Bivariate Pearson's X ² tests c	or Fisher's exact tests, e.	xcept for age (ANOV)	4).												
†Categories 'living elsewhere'	' (Belgium: n=25; the N	letherlands: n=9; Spa	in: n=6) and 'died els	ewhere' (Belgium: n=:	3; the Netherlar	ds: n=4) not shown in	n table. Home' indicat	tes living in own hom	ie or with family. 'Long	-term care facil	ity' includes residentia	al care home in Belg	ium, residential hom	he for older people in t	he

Netherlands and Spain, (infrequently) nursing home in the Netherlands. 'Hospital' excludes PCU and nursing home unit in hospital.

ANOVA, analysis of variance; PCU, palliative care unit.

_											
\mathbf{O}	ri	ai	n	a	l r	69	e,	а	r	C	h
\sim		9		4		~ ~	~	~	۰.	~	

psychological or social problems was found in BE between 2009 and 2013 (table 2), multivariable regression showed that there was a significant decrease for those aged 18–64 and those who died at home.

Trends in preferences known for medical treatments at the end of life

The percentage of people for whom the GP was aware of a preference for medical treatment they would or would not want at the end of life increased in BE (from 41% to 53%, p<0.001) and in the NL between 2009 and 2014 (from 62% to 70%, p<0.01). No significant trend was found for ES (table 2; figure 1). In multivariable regression, the increase in BE was significant for those aged 18–64 and those aged 65–84, both genders, those who lived at home in the last year of life, and those who died at home and in a palliative care unit or hospice (table 4). In the NL, the increase was significant for those aged 18–64 and 65–84, males, those who lived at home in the last year of life, and those who lived at home in the last year of life, and those who lived at home, in a hospital and in a palliative care unit or hospice.

Trends in preferences known for a proxy decision-maker

The percentage of people for whom the GP was aware of a preference for a proxy decision-maker at the end of life increased in BE (from 20% to 28%, p<0.001) and in the NL between 2009 and 2014 (from 32% to 52%, p<0.001). ES did not show a significant trend (table 2; figure 1). In multivariable regression, the increase in the percentage of people for whom the GP was aware of a preference for a proxy decision-maker at the end of life in BE was significant in those aged 18–64, those who lived in a long-term care facility in the last year of life and those who died at home (table 4). In the NL, the increase was significant in those aged 65–84 and 85+, males, those who lived at home in the last year of life and those who died at home.

DISCUSSION AND CONCLUSION Discussion

Our findings show that there has been a significant increase between 2009 and 2014 in the percentage of people with cancer with whom certain end-of-life care topics were discussed (diagnosis, GPs' awareness of a preference for medical treatment at the end of life, GPs' awareness of a preference for a proxy decision-maker). This is in line with the overall enhanced attention to patient-centred communication and ACP initiatives, focusing on the process of discussing personal goals and wishes for care and treatment at the end of life.^{14–16} However, we also found some significant decreases for other topics (options for end-of-life care, psychological or social problems). In general, these trends were found across countries and across patient groups. Although some differences between groups persist, this study shows that changes in the likelihood of communication between GPs and people with cancer are widespread and

	BE			-		The NL					ES				
	2009	2010	2013	2014		2009	2010	2013	2014		2010	2011	2013	2014	
	n=303	n=292	n=336	n=302		n=157	n=189	n=190	n=193		n=80	n=86	n=88	n=90	
	(%) N	(%) N	N (%)	(%) N	P value*	(%) N	N (%)	(%) N	(%) N	P value*	(%) N	(%) N	(%) N	(%) N	P value*
Topics discussed															
Diagnosis	241 (84)	233 (84)	275 (86)	245 (94)	<0.01	142 (96)	169 (94)	166 (97)	162 (96)	0.45	54 (79)	52 (73)	45 (76)	51 (84)	0.49
Options for end-of-life care	206 (73)	183 (67)	200 (77)	161 (90)	<0.001	127 (88)	152 (87)	120 (70)	123 (73)	<0.001	48 (76)	46 (66)	23 (39)	16 (26)	<0.001
Psychological or social problems	227 (80)	204 (74)	168 (72)	ı	0.07	136 (91)	154 (89)	135 (79)	124 (73)	<0.001	51 (77)	50 (69)	30 (51)	24 (39)	<0.001
Preference for medical treatment	123 (41)	102 (35)	178 (54)	158 (53)	<0.001	95 (62)	104 (55)	139 (74)	134 (70)	<0.01	13 (17)	9 (11)	21 (24)	20 (22)	0.06
Preference for proxy decision-maker	60 (20)	52 (18)	99 (30)	84 (28)	<0.001	49 (32)	67 (36)	100 (53)	98 (52)	<0.001	7 (9)	10 (12)	14 (16)	15 (17)	0.08
Missing data: BE 5%, NL 6%, ES 20% for 'diag decision-maker'.	nosis'; BE 17%, NL	6%, ES 21% for	'options for end-o	f-life care'; BE 15	5%, NL 9%, ES 2!	5% for 'psycholog	jical or social prot	olems'; BE 1%, N	IL 1%, ES 1% for	'preference for n	nedical treatme	nt'; BE 0%, NL	1%, ES 1% for	'preference for	proxy
*Bivariate Mantel-Haenszel tests for linear trenc	ds.														
DE Delaiton, EC Casino MI also Mashaulanda															



Figure 1 Trends in communication between general practitioners (GPs) and people with advanced cancer about end-of-life care topics in Belgium, the Netherlands and Spain, 2009–2014. Showing percentages of patients with whom certain end-of-life care topics were discussed, according to the GP, per year. Blue line shows Belgium, red line shows the Netherlands, green line shows Spain.

indicative of a change in the general population. This may also mean that similar findings could be expected for other disease groups.

To our knowledge, this study is the first trend analysis on end-of-life communication practices in primary care in Europe for people with advanced cancer. In line with previous research^{19 24} and our expectations, the international comparison of BE, the NL and ES allowed us to see that while overall trends were similar in many ways, there are considerable cross-country differences in the prevalence and magnitude of change in communication related to end-of-life care, including the overall higher frequency of end-of-life conversations in the NL and BE compared with ES. Cultural variation may play a role in these overall differences, with Southern European cultures having a stronger tendency to avoid discussions that cause distress or discomfort, trying not to take away hope.^{25 26}

Diagnosis was the most commonly discussed endof-life care topic in all three countries, a finding that is consistent with results from other cross-country attitudinal research.¹⁹ The high frequency of discussions of the diagnosis in all countries (between 84% and 96% in 2014) seems to reflect a commitment of GPs to providing people with advanced cancer with the information needed to understand their medical condition.²⁷ Awareness of their diagnosis creates an opening for patients to engage in a conversation about other implications of their illness, allowing them to exercise their autonomy. Only in BE, the increasing trend in the proportion of patients with whom the diagnosis was discussed was statistically significant; however, in the NL, a ceiling effect may have been at play, with communication already being at 96% in 2009. The increase in BE may have been due to several initiatives taking place during the 2009–2014 period, including the implementation of enhanced reimbursement to enable GPs to spend more time with patients on consultations in which the announcement of the diagnosis takes place, additional training for doctors on communication with patients, and the publishing of a protocol for disclosing the bad news about the diagnosis drafted by a group of experts.¹⁵ 16

We found that GPs' awareness of preferences for medical treatment at the end of life and awareness of preferences for a proxy decision-maker clearly increased in BE (from 41% to 53%) and in the NL (from 62% to 70%) between 2009 and 2014. Even though similar upward patterns were visible in ES, they did not reach statistical significance, possibly due to low statistical power. These aspects of ACP have numerous benefits for patients, families and professional caregivers.^{28 29}

Besides increasing trends, this study also found unexpected declines over time for some variables. The percentage of people with whom options for end-of-life care were discussed dropped between 2009 and 2014

Table 3 Trends it group in BE, the NL	n communication - and ES, 2009-	n between gene 2014 (n=2306)	ral practitioners a	and people w	ith advanced c	ancer about th	e diagnosis, op	tions for end-c	of-life care and	psychological	l or social proble	ems by patient
	Diagnosis				Options for e	nd-of-life care			Psychological	l or social problen	su	
	2009*	2014			2009*	2014			2009*	2014		
	BE: n=1201 NL: n=710 ES: n=323				BE: n=1194 NL: n=702 ES: n=320				BE: n=931 NL: n=729 ES: n=344			
Patient group	%	%	%-point change	e P valuet	%	%	%-point chan	ge P valuet	%	%	%-point chan	ge Pvaluet
Age (years)												
18-64												
BE	89	95	+6 pp	<0.001	78	92	+14 pp	<0.001	87	I	-21 pp	<0.001
The NL	100	97	-3 pp	0.68	85	74	-11 pp	0.16	93	81	-12 pp	<0.001
ES	75	94	+19 pp	0.92	94	28	-66 pp	0.07	81	44	-37 pp	<0.01
65-84												
BE	89	95	+7 pp	<0.001	78	92	+14 pp	<0.001	78	I	-2 pp	0.89
The NL	97	95	-1 pp	0.16	06	69	-21 pp	<0.001	91	71	-20 pp	<0.001
ES	80	86	+7 pp	0.61	77	31	-47 pp	<0.01	78	39	–39 pp	0.12
85+												
BE	64	89	+25 pp	<0.001	46	85	+39 pp	<0.001	68	I	-5 pp	0.07
The NL	85	97	+12 pp	0.55	85	83	—2 pp	0.05	06	73	—17 pp	<0.01
ES	84	43	—42 pp	I	50	I	I	I	71	29	—43 pp	I
Gender												
Male												
BE	84	93	+8 pp	<0.001	73	89	+16 pp	<0.001	78	I	dd 6-	0.10
The NL	96	93	–3 pp	0.07	96	93	-15 pp	<0.01	87	75	-12 pp	<0.001
ES	82	87	+5 pp	0.47	76	26	-49 pp	0.01	77	42	-35 pp	0.74
Female												
BE	84	95	+11 pp	<0.001	71	93	+21 pp	<0.001	82	1	-6 pp	0.18
The NL	96	66	+3 pp	0.75	91	75	-16 pp	<0.001	95	71	24 pp	<0.001
ES	74	78	+3 pp	0.69	78	26	-52 pp	<0.01	79	35	44 pp	<0.001
Longest place of residen	ice‡											
Home												
BE	86	95	+8 pp	<0.001	75	92	+17 pp	<0.001	81	I	-4 pp	0.25
The NL	96	96	+1 pp	0.39	87	72	—15 pp	<0.001	91	76	-15 pp	<0.001
ES	81	85	+4 pp	0.60	81	27	-54 pp	<0.001	77	41	-36 pp	0.04
Long-term care facility												
BE	63	88	+25 pp	<0.001	47	80	+33 pp	0.08	67	I	-27 pp	0.26
The NL	100	91	dd 6-	0.45	100	82	—18 pp	I	92	36	-56 pp	0.01
ES	60	50	-10 pp	I	20.0	I	I	I	80	I	I	I
Place of death‡												
Home												
BE	89	95	+6 pp	<0.001	80	94	+6 pp	<0.01	88	I	-10 pp	<0.01
												Continu

| 67 50 -17 pp - 29 72 - 72 | 67 50 – 17 pp – 29 – 29 – 72 – 72 – – – – 29 – – – – 29 – – – – – – – – | 67 50 - 17 pp - 29 - 29 - 72 - 72 - 72 - 72 - 72 - 64 - 73, 52,56 for 'diagnosis', BE 178, NL 68, ES 21% for 'options for end-of-life care', BE 158, NL 98, ES 25% for 'specindent' aniables <3%. All sing data for dependent variables. BE 58, NL 68, ES 20% for 'diagnosis', BE 178, NL 68, ES 21% for 'options' for end-of-life care', BE 158, NL 98, ES 25% for 'specindent' aniables.
 | 67 50 -17pp - 29 72
 | 67 50 -17 pp - 29 72 | | 94 85 –9p 0.02 88 77 –11pp 0.77 94 39 –55pp <0.01
 | 68 89 +22 pp <0.001 47 83 +36 pp 0.79 7430 pp 0.33 | 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp <0.01
 | 87 96 +10 pp <0.001 62 92 +30 pp <0.01 79 - 8 pp 0.40 | | 94 82 -12 pp 0.32 88 41 -47 pp <0.01 82 50 -32 pp 0.02 | 98 96 -1 pp 0.08 91 78 -14 pp <0.001 90 80 -11 pp <0.001 | % %-point change P valuet % %-point change P valuet % % %-point change P valuet %
 | s
%-point change P valuet
-11 pp <0.001
-32 pp 0.02
-8 pp 0.40
-22 pp 0.43
-33 pp 0.12
-33 pp 0.13
-53 pp 0.33
-55 pp <0.001 | l or social problem:
2014
%
80
80
50
50
78
78
78
28
28
28
28
28
28
47
47
47
47
47 | Psychological 2009* BE: n=931 NL: n=729 % % 90 90 90 100 61 73 85 73 85 73 85 73 85 73 85 74 94 | <pre>ge P valuet
<= 0.001
<= 0.01
<= 0.01
<= 0.01
<= 0.01
0.02
0.03
0.07
0.77</pre> | | 2014 2014 2014 2014 2014 2014 2014 2014 | Options for 6 2009* BE: n=1194 NL: n=702 91 % 91 88 81 77 81 83 62 77 81 83 63 63 63 63 88 <th>P valuet 0.08 0.032 0.322 0.323 0.155 0.155 0.14 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.289 0.19 0.201</th> <th></th> <th>2014
%
96
96
89
88
88
88
88</th> <th>Diagnosis 2009* 2009* BE: n=1201 NL: n=710 % % 98 94 92 65 65 65 66 67 84 94 94 94</th> | P valuet 0.08 0.032 0.322 0.323 0.155 0.155 0.14 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.289 0.19 0.201 | | 2014
%
96
96
89
88
88
88
88 | Diagnosis 2009* 2009* BE: n=1201 NL: n=710 % % 98 94 92 65 65 65 66 67 84 94 94 94 |
|---|---

--
--|---|--|---

---|---|---
---|---|---|---|---|---|--|-------------------------|---|--|--|---------------------------|---|--|
| ndent variables <3%. Missing data for dependent variables: BE 5%, NL 6%, ES 20% for 'diagnosis'; BE 17%, NL 6%, ES 21% for 'options for end-of-life care'; BE 15%, NL 9%, ES 25% for 'psychological or social problems'. | ndent variables <3%. Missing data for dependent variables: BE 5%, NL 6%, ES 20% for 'diagnosis'; BE 17%, NL 6%, ES 21% for 'options for end-of-life care'; BE 15%, NL 9%, ES 25% for 'psychological or social problems'. | modent variables <3%, Missing data for dependent variables: BE 5%, NL 6%, ES 20% for diagnosis'; BE 17%, NL 6%, ES 21% for 'options for end-of-life care'; BE 15%, NL 9%, ES 25% for 'psychological or social problems'.
 |
 | | 67 50 –17pp – 29 – – 72 – – – – – |
 | 94 85 –9 pp 0.02 88 77 –11 pp 0.77 94 39 –55 pp <0.001 | 65 89 $+24p$ 0.74 81 28 $-54p$ 0.13 61 28 $-33p$ 0.12 84 91 $+6p$ 0.19 50.79 86 $+6p$ <0.01 73 $ +6p$ 0.43 96 $-17p$ 0.389 88 828 $-6p$ 002 85 64 $-21p$ 0.43 10 8 $+22p$ 0.41 63 12 $-51p$ 0.97 100 47 $53p$ 0.73 10 8 $+22p$ 0.41 63 12 $-51p$ 0.97 100 47 $-53p$ 0.21 10 8 $+22p$ 0.41 63 12 $-51p$ 0.02 85 64 $-53p$ $0.21p$ <t< td=""><td>22 100 48p 0.15 77 39 -38p0 0.65 100 78 -22pp -0.01 65 89 +24pp 0.74 81 28 -54pp 0.13 61 28 -33pp 601 65 99 +24pp 0.74 81 28 -54pp 0.13 61 28 -33pp 0.12 84 91 +6pp 0.19 5079 86 +6pp 6.01 73 - +6pp 0.13 96 96 -17pp 0.389 88 828 -51pp 0.07 73 - +5pp 0.13 96 96 -17pp 0.389 88 828 -51pp 0.07 73 - - 71pp 0.13 97 68 12 -51pp 0.07 0.97 100 47 - 53pp 0.07 9 450p 0.07 0.79 0.79 0.79<</td><td>87 96 +10p <0.01 6.2 92 +30p <0.01 79 - 8p 0.40 92 100 +8pp 0.15 77 39 -38pp 0.85 100 78 -22pp 0.0 65 89 +24pp 0.15 77 39 -38pp 0.85 100 78 -22pp 6.01 65 89 +24pp 0.19 12 28 -54pp 0.13 61 28 -22pp 6.01 73 -33pp 6.01 79 -33pp 6.01 78 -33pp 6.01 78 -33pp 6.01 -33pp 1.05 14</td><td>87 96 +10pp <0.01 6.2 92 +30pp <0.01 79 - 8pp 0.40 92 100 +8pp 0.15 77 39 -38pp 0.85 100 78 -22pp <0.01</td> 65 89 +24pp 0.15 77 39 -38pp 0.85 100 78 -22pp <0.01</t<>
 | 22 100 48p 0.15 77 39 -38p0 0.65 100 78 -22pp -0.01 65 89 +24pp 0.74 81 28 -54pp 0.13 61 28 -33pp 601 65 99 +24pp 0.74 81 28 -54pp 0.13 61 28 -33pp 0.12 84 91 +6pp 0.19 5079 86 +6pp 6.01 73 - +6pp 0.13 96 96 -17pp 0.389 88 828 -51pp 0.07 73 - +5pp 0.13 96 96 -17pp 0.389 88 828 -51pp 0.07 73 - - 71pp 0.13 97 68 12 -51pp 0.07 0.97 100 47 - 53pp 0.07 9 450p 0.07 0.79 0.79 0.79< | 87 96 +10p <0.01 6.2 92 +30p <0.01 79 - 8p 0.40 92 100 +8pp 0.15 77 39 -38pp 0.85 100 78 -22pp 0.0 65 89 +24pp 0.15 77 39 -38pp 0.85 100 78 -22pp 6.01 65 89 +24pp 0.19 12 28 -54pp 0.13 61 28 -22pp 6.01 73 -33pp 6.01 79 -33pp 6.01 78 -33pp 6.01 78 -33pp 6.01 -33pp 1.05 14 | 87 96 +10pp <0.01 6.2 92 +30pp <0.01 79 - 8pp 0.40 92 100 +8pp 0.15 77 39 -38pp 0.85 100 78 -22pp <0.01 | 94 82 -12 p 0.32 88 41 -47 p 6.01 82 50 -32 p 0.02 87 96 +10 p <0.01 62 92 +30 p <0.01 7 <0.40 <0.40 <0.01 62 <0.9 <0.01 62 <0.01 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 <0.12 | 98 96 -1 p 0.08 91 78 -14 p <001 90 11 p <001 94 82 -12 pp 0.32 88 41 -47 pp <001 | 1 | I | 72 | I | I
 | I | 29 | I | -17 pp | 50 | 67 |
| rn for ES since data were not available for 2009. | n for ES since data were not available for 2009. | in for ES inter data were not available for 2010
 | andent variables <3%. Missing data for dependent variables: BE 5%, NL 6%, ES 20% for 'diagnoss'; BE 17%, NL 6%, ES 21% for 'options for end-oi-life care'; BE 15%, NL 9%, ES 25% for 'psychological or social problems'.
 | | | 67 50 -17pp - 29 72
 | 94 85 –9pp 0.02 88 77 –11pp 0.77 94 39 –55pp <0.001
67 50 –17pp – 29 – 2 – 72 – – – – – – | 65 89 $+24p$ 0.74 81 28 $-54p$ 0.13 61 28 $-33p$ 0.12 84 91 $+6p$ 0.19 50.79 86 $+6p$ <0.1 73 $ +6p$ 0.43 96 96 $-17p$ 0.389 88 28 $-6p$ 0.07 85 $-17p$ 0.41 67 $-17p$ 0.389 88 288 $-6p$ 0.07 87 $-6p$ 0.73 $-17p$ 0.41 63 12 $-51p$ 0.07 10 47 $-51p$ 0.07 10 10 0.73 9 88 $+22p$ -011 0.7 0.79 100 47 $-53p$ 0.27 9 88 77 $-11p$ 0.79 0.79 10 0.79 $-55p$ $-30p$ 0.23 9 50 $-17p$ $-21p$ $-21p$ $-11p$ $-52p$ <td< td=""><td>92 100 + 8p 0.15 77 39 - 38 pp 0.65 100 78 - 22 pp - 601 - 60 78 - 22 pp - 601 - 60 78 - 22 pp - 601 - 60 78 - 601 - 61 28 - 61 pp 0.13 61 28 - 61 pp 0.01 78 0.01</td><td>87 96 $+10p$ <0.01 62 92 $+3pp$ <0.01 62 $-8pp$ <0.01 <0.01</td><td>87 96 +10 pp <0.01 62 92 +30 pp <0.01 79 - 8pp 0.40 90 92 100 +8 pp 0.15 77 39 -38 pp 0.03 100 78 -22 pp <0.01</td> 65 89 +24 pp 0.14 81 28 -54 pp 0.13 61 78 -22 pp <0.01</td<> | 92 100 + 8p 0.15 77 39 - 38 pp 0.65 100 78 - 22 pp - 601 - 60 78 - 22 pp - 601 - 60 78 - 22 pp - 601 - 60 78 - 601 - 61 28 - 61 pp 0.13 61 28 - 61 pp 0.01 78 0.01
 | 87 96 $+10p$ <0.01 62 92 $+3pp$ <0.01 62 $-8pp$ <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 | 87 96 +10 pp <0.01 62 92 +30 pp <0.01 79 - 8pp 0.40 90 92 100 +8 pp 0.15 77 39 -38 pp 0.03 100 78 -22 pp <0.01 | 94 82 -12pp 0.32 88 41 -47pp 601 82 50 -32pp 0.02 87 96 +10pp 6001 62 92 +3pp 0.15 77 39 -38pp 601 79 - -8pp 0.01 92 100 +8pp 0.15 77 39 -54pp 0.13 61 78 -22pp 601 78 -22pp 601 61 601 61 | 96 -1p 0.08 91 78 -14p0 <001 90 81 -11p0 <001 94 82 -12pp 0.32 88 41 -47pp <001 | | | social problems'. | 6 for 'psychological or s | ; BE 15%, NL 9%, ES 25% | ions for end-of-life care' | NL 6%, ES 21% for 'opt | diagnosis'; BE 17%, | E 5%,
NL 6%, ES 20% for ' | or dependent variables: B
e for 2009. | Nes <3%. Missing data fo
e data were not available |
| 68 89 +22 pp <0.01 47 83 +36 pp 0.79 74 - - -30 pp 0.33 94 85 -9 pp 0.02 88 77 -11 pp 0.77 94 39 -55 pp <001 | 68 89 +22 pp <0.01 47 83 +36 pp 0.79 74 - -30 pp 0.33 94 85 -9 pp 0.02 88 77 -11 pp 0.77 94 39 -55 pp <001 | 68 89 +22 pp <0.01 47 83 +36 pp 0.79 74 - - -30 pp 0.33 94 85 -9 pp 0.02 88 77 -11 pp 0.77 94 39 -55 pp <0.001
 | 68 89 +22 pp <0.01 47 83 +36 pp 0.79 74 - - -30 pp 0.33 94 85 -9 pp 0.02 88 77 -11 pp 0.77 94 39 -55 pp <0.01
 | 68 89 +22 pp <0.01 47 83 +36 pp 0.79 74 - - -30 pp 0.33 94 85 -9 pp 0.02 88 77 -11 pp 0.77 94 39 -55 pp <0.01 | 68 89 +22 pp <0.01 47 83 +36 pp 0.79 74 - - -30 pp 0.33 94 85 -9 pp 0.02 88 77 -11 pp 0.77 94 39 -55 pp <0.001 | 68 89 +22 pp <0.001 47 83 +36 pp 0.79 7430 pp 0.33
 | | 65 89 +24 pp 0.74 81 28 -54 pp 0.13 61 28 -33 pp 0.12 1 </td <td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td> <td>87 96 +10 pp <0.01 6.2 92 +30 pp <0.01 79 - 8 pp 0.40 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp 6.01 65 89 +24 pp 0.74 81 28 -38 pp 0.85 100 78 -22 pp 6.01 65 89 +24 pp 0.74 81 28 -54 pp 0.13 61 28 -23 pp 6.01 84 91 +6 pp 0.19 50 79 86 +6 pp 0.01 73 - +6 pp 0.04 96 96 -17 pp 0.389 88 828 -6 pp 0.07 73 - 16 pp 0.43 67 88 +22 pp 0.41 63 12 -51 pp 0.07 100 47 -51 pp 0.05</td> <td>87 96 +10 pp <0.01 6.2 92 +30 pp <0.1 79 - 8 pp 0.40 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp <0.01</td> 65 89 +24 pp 0.74 81 28 -38 pp 0.13 61 78 -23 pp <0.01
 | $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | 87 96 +10 pp <0.01 6.2 92 +30 pp <0.01 79 - 8 pp 0.40 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp 6.01 65 89 +24 pp 0.74 81 28 -38 pp 0.85 100 78 -22 pp 6.01 65 89 +24 pp 0.74 81 28 -54 pp 0.13 61 28 -23 pp 6.01 84 91 +6 pp 0.19 50 79 86 +6 pp 0.01 73 - +6 pp 0.04 96 96 -17 pp 0.389 88 828 -6 pp 0.07 73 - 16 pp 0.43 67 88 +22 pp 0.41 63 12 -51 pp 0.07 100 47 -51 pp 0.05 | 87 96 +10 pp <0.01 6.2 92 +30 pp <0.1 79 - 8 pp 0.40 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp <0.01 | 94 82 -12 pp 0.32 88 41 -47 pp <0.01 82 50 -32 pp 0.02 87 96 +10 pp <0.01 | 98 96 -1pp 0.08 91 78 -14pp 6.001 90 80 -11pp 6.001 94 82 -12pp 0.32 88 41 -47pp 6.01 90 80 -11pp 6.001 87 96 +10pp 6.001 62 92 +30pp 6.01 82 -32pp 0.02 87 96 +10pp 6.001 62 92 +30pp 6.01 79 -8pp 0.02 87 100 +8pp 0.15 77 39 -38pp 0.85 100 78 -22pp 0.10 10 +4pp 0.14 81 28 -54pp 0.13 61 28 -33pp 0.12 10 +4pp 0.14 81 28 -54pp 0.13 61 28 -33pp 0.12 10 10 10
 10 10 10 10 10 10 10< | | | | | | | | | | | |
| ty
68 89 +22 pp <0.01 47 83 +36 pp 0.79 7430 pp 0.33
94 85 -9 pp 0.02 88 77 -11 pp 0.77 94 39 -55 pp 0.33
67 -17 pp - 29 29 29 29 29 29 29 29 29 29 72 72 72 72 | ty
68 89 +22 pp <0.001 47 83 +36 pp 0.79 7430 pp 0.33
94 85 -9 pp 0.02 88 77 -11 pp 0.77 94 39 -55 pp -3001
67 -17 pp - 29 - 29 29 29 29 29 | Ity
68 89 +22 pp <0.001 47 83 +36 pp 0.79 7430 pp 0.33
94 85 -9 pp 0.02 88 77 -11 pp 0.77 94 39 -55 pp 0.001
67 50 -17 pp - 29 7 72 - 72
 | ity
68 89 +22 pp <0.001 47 83 +36 pp 0.79 7430 pp 0.33
94 85 -9 pp 0.02 88 77 -11 pp 0.77 94 39 -55 pp <0.001
67 50 -17 pp - 29 72
 | iy
68 89 +22 pp <0.001 47 83 +36 pp 0.79 7430 pp 0.33
94 85 -9 pp 0.02 88 77 -11 pp 0.77 94 39 -55 pp <0.001
67 50 -17 pp - 29 | iy
68 89 +22 pp <0.001 47 83 +36 pp 0.79 7430 pp 0.33
94 85 -9 pp 0.02 88 77 -11 pp 0.77 94 39 -55 pp <0.001 | ty
68 89 +22 pp <0.001 47 83 +36 pp 0.79 74 − −30 pp 0.33
 | jy de la companya de | 65 89 +24 pp 0.74 81 28 -54 pp 0.13 61 28 -33 pp 0.12 1 <t< td=""><td>22 100 +8pp 0.15 77 39 -38pp 0.85 100 78 -22pp <0.01</td> 65 89 +24pp 0.74 81 28 -54pp 0.13 61 28 -33pp 0.12 84 91 +6pp 0.19 50.79 86 +6pp <0.01</t<>
 | 22 100 +8pp 0.15 77 39 -38pp 0.85 100 78 -22pp <0.01 | 87 96 +10 pp <0.01 62 92 +30 pp <0.01 79 - 8 pp 0.40 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp 6.01 65 89 +24 pp 0.74 81 28 -54 pp 0.13 61 28 -23 pp 6.01 84 91 +6 pp 0.74 81 28 -54 pp 0.13 61 28 -33 pp 6.01 84 91 +6 pp 0.19 50 79 86 +6 pp 6.01 73 -33 pp 0.12 84 91 -17 pp 0.389 88 828 -6 pp 0.02 85 -6 pp 0.40 | 87 96 +10 pp <0.01 62 92 +30 pp <0.01 79 - 8 pp 0.40 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp <0.01 | 94 82 -12 pp 0.32 88 41 -47 pp <0.01 82 50 -32 pp 0.02 87 96 +10 pp <0.01 | 98 96 -1 pp 0.08 91 78 -14 pp <001 90 80 -11 pp <001 94 82 -12 pp 0.32 88 41 -47 pp <001
 | –53 pp 0.27 | 47 | 100 | 0.97 | —51 рр | 12 | 63 | 0.41 | +22 pp | 88 | 67 |
| 67 88 + +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 ty 68 89 + 22 pp <0001 | 67 88 + 22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 1y 68 89 + 22 pp <0011 | 67 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 V 68 89 +22 pp <0.010
 | 67 88 +22pp 0.41 63 12 -51pp 0.97 100 47 -53pp 0.27 V 68 89 +22pp <0.01
 | 67 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 V 68 89 +22 pp <0.01 | 67 88 +22pp 0.41 63 12 -51pp 0.97 100 47 -53pp 0.27 ty 68 89 +22pp <0.01 | 67 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 ty 68 89 +22 pp <0.01
 | 67 88 +22.pp 0.41 63 12 –51.pp 0.97 100 47 –53.pp 0.27
ly | 65 89 +24pp 0.74 81 28 -54pp 0.13 61 28 -33pp 0.12
84 91 +6pp 0.19 50.79 86 +6pp <0.01 73 - +6pp 0.43
 | 92 100 +8pp 0.15 77 39 -38pp 0.85 100 78 -22pp <0.01 65 89 +24pp 0.74 81 28 -54pp 0.13 61 28 -33pp 601 65 89 +24pp 0.74 81 28 -54pp 0.13 61 28 -33pp 0.12 84 91 +6pp 0.19 50.79 86 +6pp <0.01 | 87 96 +10pp <0.01 62 92 +30pp <0.01 79 - - 8pp 0.40 92 100 +8pp 0.15 77 39 -38pp 0.85 100 78 -22pp 6.01 65 89 +24pp 0.14 81 28 -54pp 0.13 61 28 -23pp 6.01 65 89 +24pp 0.74 81 28 -54pp 0.13 61 28 -33pp 6.01 84 91 +6p 0.19 50.79 86 +6pp 6.01 78 -33pp 6.01 | 87 96 +10 pp <0.01 62 92 +30 pp <0.1 79 - 8 pp 0.40 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp <0.01 | 94 82 -12pp 0.32 88 41 -47pp <0.01 82 50 -32pp 0.02 87 96 +10pp <0.01 | 98 96 -1 pp 0.08 91 78 -14 pp <001 90 80 -11 pp <001 94 82 -12 pp 0.32 88 41 -47 pp <001
 | -21 pp 0.05 | 64 | 85 | 0.02 | -6 pp | 828 | 88 | 0.389 | -17 pp | 96 | 96 |
| 96 96 -17 pp 0.389 88 8.28 -6 pp 0.02 85 64 -21 pp 0.05 1y 1 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.07 1y 1 12 -51 pp 0.97 100 47 -53 pp 0.27 1y 1 12 -51 pp 0.97 100 47 -53 pp 0.27 1 8 +22 pp <0.01 | 96 96 -17 pp 0.389 88 8.28 -6 pp 0.02 85 64 -21 pp 0.05 1y 1 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.07 1y 1 12 -51 pp 0.97 100 47 -53 pp 0.27 1y 1 12 -51 pp 0.97 100 47 -53 pp 0.27 1 8 +22 pp <0.01 | 96 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.05 1y 67 88 +22 pp 0.41 63 12 -51 pp 0.07 47 -53 pp 0.07 1y 67 88 +22 pp 0.41 63 12 -51 pp 0.07 47 -53 pp 0.27 1y 68 89 +22 pp <0.01
 | 96 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.05 17 88 +22 pp 0.41 63 12 -51 pp 0.07 85 64 -21 pp 0.07 17 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 18 68 89 +22 pp <0.01
 | 96 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.05 67 88 +22 pp 0.41 63 12 -51 pp 0.07 100 47 -53 pp 0.27 ity 67 89 +22 pp 0.01 47 83 +36 pp 0.79 100 47 -53 pp 0.27 ity 68 89 +22 pp <001 | 96 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.05 67 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 ity 67 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 ity 68 89 +22 pp <0.01 | 96 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.05 67 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 ity 67 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 ity 68 89 +22 pp <0.01
 | 96 96 -17pp 0.389 88 828 -6pp 0.02 85 64 -21pp 0.05
67 88 +22pp 0.41 63 12 -51pp 0.97 100 47 -53pp 0.27
ity | 65 89 +24 pp 0.74 81 28 -54 pp 0.13 61 28 -33 pp 0.12
 | 92 100 +8pp 0.15 77 39 -38pp 0.85 100 78 -22pp <0.01
65 89 +24pp 0.74 81 28 -54pp 0.13 61 28 -33pp 0.12
0.12 | 87 96 +10 pp <0.01 62 92 +30 pp <0.01 79 - - 8 pp 0.40 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp <0.01 | 87 96 +10 pp <0.01 62 92 +30 pp <0.01 79 - 8 pp 0.40
92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp <0.01
65 89 +24 pp 0.74 81 28 -54 pp 0.13 61 28 -33 pp 0.12 | 94 82 -12 pp 0.32 88 41 -47 pp <0.01 82 50 -32 pp 0.02 87 96 +10 pp <0.01 | 98 96 -1 pp 0.08 91 78 -14 pp <001 90 80 -11 pp <001 94 82 -12 pp 0.32 88 41 -47 pp <001
 | +6 pp 0.43 | I | 73 | <0.01 | +6 pp | 86 | 50 79 | 0.19 | +6 pp | 91 | 84 |
| 84 91 +6 pp 0.19 50 79 86 +6 pp <01 73 - +6 pp 0.43 96 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.05 10 67 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.05 11 12 12 -51 pp 0.97 100 47 -53 pp 0.07 12 12 12 -51 pp 0.97 100 47 -53 pp 0.03 13 12 12 -11 pp 0.79 14 -53 pp 0.03 14 85 -9 pp 0.02 83 77 -11 pp 0.79 74 -50 pp -51 pp | 84 91 +6 pp 0.19 50 79 86 +6 pp <01 73 - +6 pp 0.43 96 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.03 17 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.03 18 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.03 19 88 +22 pp <001 | 84 91 +6 pp 0.19 50 79 86 +6 pp <0.01 73 - +6 pp 0.43 96 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.05 10 67 88 +22 pp 0.41 63 12 -51 pp 0.07 87 -51 pp 0.05 13 67 88 +22 pp 0.41 63 12 -51 pp 0.07 47 -53 pp 0.27 14 68 89 +22 pp <001
 |
 | 84 91 +6pp 0.19 50.79 86 +6pp <0.01 73 - +6pp 0.43 96 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.03 96 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.05 13 67 88 +22 pp 0.41 63 12 -51 pp 0.07 130 47 53 pp 0.27 13 67 88 +22 pp 0.011 47 83 +36 pp 0.79 74 - - - 50 pp 0.33 14 83 - - 11 pp 0.77 94 39 - | 84 91 +6pp 0.19 50.79 86 +6pp <0.01 73 - +6pp 0.43 96 96 -17pp 0.389 88 828 -6pp 0.02 85 64 -21pp 0.05 67 88 +22pp 0.41 63 12 -51pp 0.97 100 47 -53pp 0.27 19 67 89 +22pp 0.41 63 12 -51pp 0.97 100 47 -53pp 0.27 19 68 89 +22pp <001 |
 | 84 91 +6pp 0.19 50.79 86 +6pp <0.1 73 - +6pp 0.43 96 96 -17pp 0.389 88 828 -6pp 0.02 85 64 -21pp 0.05 67 88 +22pp 0.41 63 12 -51pp 0.97 100 47 -53pp 0.27 ity 1 63 12 -51pp 0.97 100 47 -53pp 0.27 | 65 89 +24 pp 0.74 81 28 -54 pp 0.13 61 28 -33 pp 0.12
 | 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp <0.01 65 89 +24 pp 0.74 81 28 -54 pp 0.13 61 28 -33 pp 0.12 | 87 96 +10 pp <0.01 62 92 +30 pp <0.01 79 - -8 pp 0.40 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp <0.01 | 87 96 +10 pp <0.001 62 92 +30 pp <0.01 79 - -8 pp 0.40 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp <0.01 | 94 82 -12 pp 0.32 88 41 -47 pp <0.01 82 50 -32 pp 0.02 87 96 +10 pp <0.01 | 98 96 -1 pp 0.08 91 78 -14 pp <001 90 80 -11 pp <0.01 94 82 -12 pp 0.32 83 41 -47 pp <0.01 |
 | | | | | | | | | | |
| 84 91 +6 pp 0.19 50 79 86 +6 pp <01 73 - +6 pp 0.43 96 96 -17 pp 0.389 88 828 -6 pp 002 85 64 -21 pp 0.05 10 67 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 11 88 +22 pp 0.41 63 +46 pp 0.07 100 47 -53 pp 0.27 11 88 12 -51 pp 0.07 0.79 74 -53 pp 0.23 12 64 71 0.17 0.79 74 -53 pp 0.23 12 -50 -17 pp - 23 -55 pp 0.33 13 -55 pp - - - - - - - - - - - - - - - - | 84 91 46 pp 0.19 50 79 86 46 pp <01 73 - 46 pp 0.43 96 96 -17 pp 0.389 88 828 -6 pp 002 85 64 -21 pp 0.05 10 67 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 11 8 +22 pp 0.41 63 +12 pp 0.01 47 -53 pp 0.27 12 - 12 -51 pp 0.07 100 47 -53 pp 0.23 13 - - - - - - -53 pp 0.23 14 85 - - 10 0.73 - - -53 pp 0.23 15 - - - 11 pp 0.79 74 - - - - - - - | 84 91 +6 pp 0.19 50 79 86 +6 pp <0.01 73 - +6 pp 0.43 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.05 10 67 88 +22 pp 0.41 63 12 -51 pp 0.07 87 -51 pp 0.05 11 67 88 +22 pp 0.41 63 12 -51 pp 0.07 47 -53 pp 0.27 11 68 89 +22 pp -60001 47 83 +36 pp 0.79 74 - -30 pp 0.33 12 50 -17 pp - 29 - -11 pp 0.33 -
 | 84 91 +6pp 0.19 50.79 86 +6pp <0.01 73 - +6pp 0.43 96 96 -17pp 0.389 88 828 -6pp 0.02 85 64 -21pp 0.03 10 8 +22pp 0.41 63 12 -51pp 0.02 85 64 -21pp 0.05 11 8 +22pp 0.41 63 12 -51pp 0.97 100 47 -53pp 0.27 11 8 +22pp <001
 | 84 91 +6pp 0.19 50.79 86 +6pp <0.01 | 84 91 +6pp 0.19 50.79 86 +6pp <0.01 73 - +6pp 0.43 96 96 -17pp 0.389 88 828 -6pp 0.02 85 64 -21pp 0.05 67 88 +22pp 0.41 63 12 -51pp 0.07 85 64 -53pp 0.27 10 88 +22pp 0.41 63 12 -51pp 0.07 100 47 -53pp 0.27 10 88 +22pp 0.41 63 12 -51pp 0.07 100 47 -53pp 0.27 10 88 +22pp -0.01 47 83 -53pp 0.27 -53pp 0.23 10 83 +36pp 0.79 100 74 - -53pp 0.33 10 83 -7 -11pp 0.79 94 - -50pp -50pp -50pp | 84 91 +6pp 0.19 50 79 86 +6pp <01 73 - +6pp 0.43 96 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.05 10 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 11 67 88 +22 pp 0.41 63 12 -51 pp 0.97 100 47 -53 pp 0.27 11 68 89 +22 pp 0.01 47 83 +56 pp 0.79 74 - -53 pp 0.27 11 68 89 +22 pp 6.001 47 83 +56 pp 0.79 74 - -50 pp 0.33
 | 84 91 +6pp 0.19 50 79 86 +6pp <01 73 - +6pp 0.43 96 96 -17 pp 0.389 88 828 -6 pp 0.02 85 64 -21 pp 0.05 67 88 12 -51 pp 0.07 85 64 -21 pp 0.05 1ty 88 12 -51 pp 0.97 100 47 -53 pp 0.27 |
 | 92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp < 0.01 | 87 96 +10 pp <0.001 62 92 +30 pp <0.01 79 - 8 pp 0.40
92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp <0.01 | 87 96 +10 pp <0.001 62 92 +30 pp <0.01 798 pp 0.40
92 100 +8 pp 0.15 77 39 -38 pp 0.85 100 78 -22 pp <0.01 | 94 82 -12 pp 0.32 88 41 -47 pp <0.01 82 50 -32 pp 0.02 87 96 +10 pp <0.01 | 98 96 -1 pp 0.08 91 78 -14 pp <001 90 80 -11 pp <0.01 94 82 -12 pp 0.32 88 41 -47 pp <0.01
 | –33 pp 0.12 | 28 | 61 | 0.13 | -54 pp | 28 | 81 | 0.74 | +24 pp | 89 | 65 | | | | | | | | | | | | | | |
| % | % | % | % % %-point change Name Name Name Name Name Name </td <td>% %</td> <td>% %</td> <td>% %</td> <td>% %</td> <td>% %</td> <td>% % %-point change P valuet %<td>% %</td><td>% %-point change P valuet % %-point change P valuet %-point change P valuet %-point change P valuet % %-point change P valuet</td><td>% %-point change P valuet % %-point change P valuet % % %-point change P valuet %</td><td></td><td> </td><td></td><td>BE: n=931
NL: n=729
ES: n=344</td><td></td><td>I</td><td></td><td>BE: n=1194
NL: n=702
ES: n=320</td><td></td><td></td><td></td><td>BE: n=1201
NL: n=710
ES: n=323</td></td> | % | % | % | % | % | % % %-point change P valuet % <td>% %</td> <td>% %-point change P valuet % %-point change P valuet %-point change P valuet %-point change P valuet % %-point change P valuet</td> <td>% %-point change P valuet % %-point change P valuet % % %-point change P valuet %</td> <td></td> <td> </td> <td></td> <td>BE: n=931
NL: n=729
ES: n=344</td> <td></td> <td>I</td> <td></td> <td>BE: n=1194
NL: n=702
ES: n=320</td> <td></td> <td></td> <td></td> <td>BE: n=1201
NL: n=710
ES: n=323</td> | % | % %-point change P valuet %-point change P valuet %-point change P valuet % %-point change P valuet | % %-point change P valuet % %-point change P valuet % % %-point change P valuet % | | | | BE: n=931
NL: n=729
ES: n=344 | | I | | BE: n=1194
NL: n=702
ES: n=320 | | | | BE: n=1201
NL: n=710
ES: n=323 |
| Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed | Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed
Energed | Efficient of the sector of the sect | Beneloti
Number 100 | Bit manual line Bit manua | Bit in a 10 to the interval | Bit = 1201 Bit = 1 | Bit in 1201 Bit in 1201 <td>BE:n=120 BE:n=120 BE:n=134 BE:n=314 BE:n=331 BE:n=331</td> <td>B: n=101 B: n=104 B: n=104 B: n=31 B: n=1 B: n=1</td> <td>BE:n=1201 BE:n=134 BE:n=134 NL:n=710 NL:n=702 ES:n=343 % %-pointchange Ye % % %-pointchange Ye 98 96 -1pp 0.08 91 78 -14pp 6.001 90 80 -11pp 6.001 94 82 -12p 0.32 88 41 -47pp 6.01 80 -11pp 6.001</td> <td>BE: n=1201 BE: n=124 BE: n=124 NL: n=710 NL: n=702 SE: n=344 NL: n=723 SE: n=344 NL: n=723 % %-point change P valuet % %-point change P valuet 9 96 -1 p 0.08 91 78 -11 pp c001 90 80 -11 pp c001 200 2001 c001 200 c001 c001 c001 c001 c001 c001 c000 c00 c00 c000 c00 c00 c00 c00 c00 c00 c0<td>BE: n=1201 BE: n=194 BE: n=194 NL: n=710 NL: n=702 BE: n=931 S: n=323 NL: n=729 SI: n=729 65: n=324 SI: n=344 SI: n=344 % % %-point change P valuet % -point change P valuet</td><td>BE: n=1201 BE: n=1194 BE: n=931 NL: n=710 NL: n=702 NL: n=729 ES: n=323 ES: n=320 ES: n=344</td><td></td><td>2014</td><td>2009*</td><td></td><td></td><td>2014</td><td>2009*</td><td></td><td></td><td>2014</td><td>2009*</td></td> | BE:n=120 BE:n=120 BE:n=134 BE:n=314 BE:n=331 | B: n=101 B: n=104 B: n=104 B: n=31 B: n=1 | BE:n=1201 BE:n=134 BE:n=134 NL:n=710 NL:n=702 ES:n=343 % %-pointchange Ye % % %-pointchange Ye 98 96 -1pp 0.08 91 78 -14pp 6.001 90 80 -11pp 6.001 94 82 -12p 0.32 88 41 -47pp 6.01 80 -11pp 6.001 | BE: n=1201 BE: n=124 BE: n=124 NL: n=710 NL: n=702 SE: n=344 NL: n=723 SE: n=344 NL: n=723 % %-point change P valuet % %-point change P valuet 9 96 -1 p 0.08 91 78 -11 pp c001 90 80 -11 pp c001 200 2001 c001 200 c001 c001 c001 c001 c001 c001 c000 c00 c00 c000 c00 c00 c00 c00 c00 c00 c0 <td>BE: n=1201 BE: n=194 BE: n=194 NL: n=710 NL: n=702 BE: n=931 S: n=323 NL: n=729 SI: n=729 65: n=324 SI: n=344 SI: n=344 % % %-point change P valuet % -point change P valuet</td> <td>BE: n=1201 BE: n=1194 BE: n=931 NL: n=710 NL: n=702 NL: n=729 ES: n=323 ES: n=320 ES: n=344</td> <td></td> <td>2014</td> <td>2009*</td> <td></td> <td></td> <td>2014</td> <td>2009*</td> <td></td> <td></td> <td>2014</td> <td>2009*</td> | BE: n=1201 BE: n=194 BE: n=194 NL: n=710 NL: n=702 BE: n=931 S: n=323 NL: n=729 SI: n=729 65: n=324 SI: n=344 SI: n=344 % % %-point change P valuet % -point change P valuet | BE: n=1201 BE: n=1194 BE: n=931 NL: n=710 NL: n=702 NL: n=729 ES: n=323 ES: n=320 ES: n=344 | | 2014 | 2009* | | | 2014 | 2009* | | | 2014 | 2009* |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | | jooting jooting </td <td></td> <td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td> <td></td> <td>300* 2014 <t< td=""><td>200* 2014 2004 2014 2004 2014 <th< td=""><td></td><td></td><td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td><td>2009* 2014 2009* 2014 BE:n=1201 E:n=1201 2014 2014 NL:n=710 E:n=1201 E:n=134 E:n=31 NL:n=710 NL:n=720 E:n=31 E:n=321 % % %-point change %-point change %-point change % % %-point change %-point change %-point change %-point change % % %-point change %-point change %-point change %-point change %-point change %-point change % % %-point change % %-point change %-point change<td>2009* 2014 2009* 2014 BE: n=1201 BE: n=1204 2014 2014 NL: n=710 NL: n=729 BE: n=931 NL: n=729 S: n=323 S: n=320 S: n=344 S: n=344 % % %-point change P valuet % -point change P valuet</td><td>2009* 2014 2004* 2014 2004* 2014 BE: n=1201 BE: n=194 BE: n=931 NL: n=729 NL: n=729 ES: n=344 D: n=223 ES: n=320 ES: n=320 ES: n=344 ES: n=344 ES: n=344 ES: n=344</td><td>S</td><td>l or social problems</td><td>Psychologica</td><td></td><td></td><td>end-of-life care</td><td>Options for 6</td><td></td><td></td><td></td><td>Diagnosis</td></td></th<></td></t<></td> | | $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | | 300* 2014 <t< td=""><td>200* 2014 2004 2014 2004 2014 <th< td=""><td></td><td></td><td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td><td>2009* 2014 2009* 2014 BE:n=1201 E:n=1201 2014 2014 NL:n=710 E:n=1201 E:n=134 E:n=31 NL:n=710 NL:n=720 E:n=31 E:n=321 % % %-point change %-point change %-point change % % %-point change %-point change %-point change %-point change % % %-point change %-point change %-point change %-point change %-point change %-point change % % %-point change % %-point change %-point change<td>2009* 2014 2009* 2014 BE: n=1201 BE: n=1204 2014 2014 NL: n=710 NL: n=729 BE: n=931 NL: n=729 S: n=323 S: n=320 S: n=344 S: n=344 % % %-point change P valuet % -point change P valuet</td><td>2009* 2014 2004* 2014 2004* 2014 BE: n=1201 BE: n=194 BE: n=931 NL: n=729 NL: n=729 ES: n=344 D: n=223 ES: n=320 ES: n=320 ES: n=344 ES: n=344 ES: n=344 ES: n=344</td><td>S</td><td>l or social problems</td><td>Psychologica</td><td></td><td></td><td>end-of-life care</td><td>Options for 6</td><td></td><td></td><td></td><td>Diagnosis</td></td></th<></td></t<> | 200* 2014 2004 2014 2004 2014 <th< td=""><td></td><td></td><td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td><td>2009* 2014 2009* 2014 BE:n=1201 E:n=1201 2014 2014 NL:n=710 E:n=1201 E:n=134 E:n=31 NL:n=710 NL:n=720 E:n=31 E:n=321 % % %-point change %-point change %-point change % % %-point change %-point change %-point change %-point change % % %-point change %-point change %-point change %-point change %-point change %-point change % % %-point change % %-point change %-point change<td>2009* 2014 2009* 2014 BE: n=1201 BE: n=1204 2014 2014 NL: n=710 NL: n=729 BE: n=931 NL: n=729 S: n=323 S: n=320 S: n=344 S: n=344 % % %-point change P valuet % -point change P valuet</td><td>2009* 2014 2004* 2014 2004* 2014 BE: n=1201 BE: n=194 BE: n=931 NL: n=729 NL: n=729 ES: n=344 D: n=223 ES: n=320 ES: n=320 ES: n=344 ES: n=344 ES: n=344 ES: n=344</td><td>S</td><td>l or social problems</td><td>Psychologica</td><td></td><td></td><td>end-of-life care</td><td>Options for 6</td><td></td><td></td><td></td><td>Diagnosis</td></td></th<> | | | $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | 2009* 2014 2009* 2014 BE:n=1201 E:n=1201 2014 2014 NL:n=710 E:n=1201 E:n=134 E:n=31 NL:n=710 NL:n=720 E:n=31 E:n=321 % % %-point change %-point change %-point change % % %-point change %-point change %-point change %-point change % % %-point change %-point change %-point change %-point change %-point change %-point change % % %-point change % %-point change %-point change <td>2009* 2014 2009* 2014 BE: n=1201 BE: n=1204 2014 2014 NL: n=710 NL: n=729 BE: n=931 NL: n=729 S: n=323 S: n=320 S: n=344 S: n=344 % % %-point change P valuet % -point change P valuet</td> <td>2009* 2014 2004* 2014 2004* 2014 BE: n=1201 BE: n=194 BE: n=931 NL: n=729 NL: n=729 ES: n=344 D: n=223 ES: n=320 ES: n=320 ES: n=344 ES: n=344 ES: n=344 ES: n=344</td> <td>S</td> <td>l or social problems</td> <td>Psychologica</td> <td></td> <td></td> <td>end-of-life care</td> <td>Options for 6</td> <td></td> <td></td> <td></td> <td>Diagnosis</td> | 2009* 2014 2009* 2014 BE: n=1201 BE: n=1204 2014 2014 NL: n=710 NL: n=729 BE: n=931 NL: n=729 S: n=323 S: n=320 S: n=344 S: n=344 % % %-point change P valuet % -point change P valuet | 2009* 2014 2004* 2014 2004* 2014 BE: n=1201 BE: n=194 BE: n=931 NL: n=729 NL: n=729 ES: n=344 D: n=223 ES: n=320 ES: n=320 ES: n=344 ES: n=344 ES: n=344 ES: n=344 | S | l or social problems | Psychologica | | | end-of-life care | Options for 6 | | | | Diagnosis |

Home indicates living in own home or with family. "Long-term care facility' includes residential care home in Belgium, residential home for older people in the Netherlands and ES, (infrequently) nursing home in the Netherlands. 'Hospital' excludes PCU and nursing home with in hospital BE, Belgium; ES, Spain; NL, the Netherlands; PCU, palliative care unit; pp, percentage point (calculated using the first and last available year). BMJ Support Palliat Care: first published as 10.1136/bmjspcare-2019-001999 on 27 April 2020. Downloaded from http://spcare.bmj.com/ on May 5, 2020 by guest. Protected by copyright.

Table	4 Trends in awa	areness by genera	I practitioners of	preferences of	f people with	advanced	cancer f	or medical	treatment a	and for a	а
proxy	decision-maker by	patient group in	BE, the NL and E	S, 2009–2014	(n=2306)						

1		9	-,,,,,		,				
		Patient expr	essed preference for m	edical treatm	nent	Patient ex	pressed preference for p	roxy decision-	maker
		2009*	2014			2009*	2014		
		BE: n=1233	NL: n=729 ES: n=344	0/		BE: n=123	3 NL: n=729 ES: n=344	0/ maint	
Patient	group	%	%	%-point change	pt	%	%	– %-point change	pt
	18-64				· ·				
Age (Jears)	Belgium	42	48	+7 nn	<0.001	19	37	+18 pp	0.01
	The Netherlands	58	68	+10 pp	0.05	36	39	+3 pp	0.38
	Spain	29	36	+7 pp	0.2	12	18	+6 pp	_
	65-84	20	50	1.1 PP	012		10	i e pp	
	Belgium	41	58	+18 pp	<0.001	19	25	+7 pp	0.62
	The Netherlands	63	67	+4 pp	< 0.01	29	51	+23 pp	0.02
	Spain	17	20	+3 pp	0.15	11	16	+5 pp	0.51
	85+			. 11				. 11	
	Belgium	40	46	+5 aa	0.1	23	26	+3 pp	0.27
	The Netherlands	63	83	+20 pp	0.06	32	63	+31 pp	0.05
	Spain	-	12	-	-	-	18	-	-
Gender	Male								
	Belgium	39	54	+15 pp	<0.001	21	35	+14 pp	0.18
	The Netherlands	51	73	+22 pp	< 0.001	14	48	+35 pp	< 0.001
	Spain	20	17	-3 pp	0.14	9	10	+1 pp	0.4
	Female								
	Belgium	43	52	+9 pp	<0.01	18	20	+2 pp	0.6
	The Netherlands	72	67	-4 pp	0.11	48	55	+7 pp	0.86
	Spain	9	32	+26 pp	0.83	8	29	+21 pp	0.89
Longest place of residence‡	Home								
	Belgium	41	57	+16 pp	<0.001	19	29	+10 pp	0.08
	The Netherlands	64	71	+7 pp	< 0.001	33	52	+19 pp	< 0.01
	Spain	18	23	+6 pp	0.17	10	17	+8 pp	0.51
	Long-term care facility								
	Belgium	32	35	+3 pp	0.7	27	22	—5 pp	0.04
	The Netherlands	43	69	+26 pp	0.95	14	39	+24 pp	0.8
	Spain	-	-	-	-	-	-	-	-
Place of death‡	Home								
	Belgium	55	73	+18 pp	< 0.001	20	41	+21 pp	<0.01
	The Netherlands	76	82	+6 pp	< 0.001	41	66	+25 pp	<0.01
	Spain	21	27	+7 pp	0.02	8	16	+9 pp	0.08
	Hospital								
	Belgium	33	33	0 pp	0.71	15	14	0 pp	0.2
	The Netherlands	50	39	—11 рр	0.05	21	15	—6 рр	0.26
	Spain	13	25	+12 pp	0.6	4	21	+17 pp	0.48
	PCU/hospice								
	Belgium	39	60	+21 pp	<0.01	26	22	-4 pp	0.13
	The Netherlands	35	68	+34 pp	<0.01	23	46	+22 pp	0.37
	Spain	20	17	-3 pp	0.18	30	17	—13 pp	0.74
	Long-term care facility								
	Belgium	29	44	+15 pp	0.53	24	27	+3 pp	0.18
	The Netherlands	53	60	+7 pp	0.97	18	33	+16 pp	0.14
	Spain	-	_	_	_	_	-	-	_

Missing data for independent variables <3%. Missing data for dependent variables: BE 1%, NL 1%, ES 1% for 'preference for medical treatment'; BE 0%, NL 1%, ES 1% for 'preference for proxy decisionmaker'

*The year 2010 is shown for Spain since data were not available for 2009.

+Multivariable trend analysis controlled for age, gender, primary cancer site, longest place of residence in the last year of life, place of death. In some cases significance tests could not be performed due to small n.

‡'Home' indicates living in own home or with family. 'Long-term care facility' includes residential care home in Belgium, residential home for older people in the Netherlands and Spain, (infrequently) nursing home in the Netherlands. 'Hospital' excludes PCU and nursing home unit in hospital.

BE, Belgium; ES, Spain; NL, the Netherlands; PCU, palliative care unit; %-point and pp, percentage point (calculated using the first and last available year).

in the NL (from 88% to 73%) and to an even more extreme extent in ES (from 74% to 26%). Furthermore, again in the NL and in ES, a decline was seen in the percentages of people with whom psychological or social problems were discussed (from 91% to 73% and from 77% to 39%, respectively). These two items were the only items which have undergone minor modifications to their formulation. This could have influenced interpretation. However, the downward trends were already visible within the first wave (from 2009 to 2010 in the NL and from 2010 to 2011 in ES) and therefore the impact of changes in phrasing may have been limited. Additionally, the new formulation of the question (from 'palliative care' to 'end-of-life care'), which was explicitly intended to allow respondents to imagine a wider range of care provided beyond specialised palliative care, could equally have been expected to result in an increase in the response. A Belgian study found that medical oncologists perceive the term 'palliative care' as a barrier to communication about end-of-life care due to the stigma associated with the term, and in BE we indeed saw an increase in reported communication once this term had been removed from the questionnaire.³⁰ However, there are also indications that the term 'endof-life care' carries a stigma of its own in certain cultures, and is not well defined in all contexts.³¹ As such, these conflicting pressures may be responsible for some of the changes over time.

Other explanations for these unexpected decreases exist. One possible interpretation is related to an increase in the specialisation of cancer care and palliative care. Due to suboptimal information transmission between GPs and specialists, it is not uncommon for GPs and their patients to lose touch during ongoing treatment and in the post-treatment phases.³² In ES, for example, palliative care in hospitals has improved considerably over the course of this study, possibly leading to an increase in end-of-life conversations taking place in the hospital instead of the primary care setting.¹⁴ In the NL, a recent study showed that GPs were more hesitant to engage in ACP with patients who were still being treated by specialists in hospital, as these patients are often less open to discussion.³³ Numerous initiatives have been developed to make earlier integration of specialised palliative care services a reality.^{34–37} Consequently, certain topics may be more frequently discussed with palliative caregivers or nurses of the palliative homecare team rather than with GPs. An interesting example is the evolving role of the oncology nurse in clinical oncology departments.^{38,39} These nurses pay particular attention to the emotional impact of living with and beyond the diagnosis and its treatment through the cancer care pathway.⁴⁰ This still does not explain why these decreases were only found for the NL and ES, and not for BE, where the role of the oncology nurse is well defined and highly appreciated.⁴¹ The way palliative care provision is organised may contribute to part of the differences. BE and the NL are small countries where palliative care is often

highly accessible, whereas in ES, despite improvements in recent years, palliative care provision in rural areas is still lacking.¹⁴

The mortality follow-back study design is a robust study design to measure end-of-life care on a population level.⁴² In this study, recall bias was limited since GPs were instructed to complete the questionnaire within a week of the patient's death. A limitation is that although representative within this area, the Spanish Sentinel Network only covered a specific region resulting in a smaller sample and lower statistical power. Furthermore, this study only reports if topics were discussed according to the GP, and does not represent the totality of end-of-life communication with patients with cancer. Perceptions of what constitutes the 'discussion' of a certain topic may differ between patients and physicians.⁴³ The present study examines the prevalence of discussions and can neither provide in-depth insights into patients' expectations or desires for such conversations-for example, whether patients took the initiative for such communication themselves or whether they rely on their GP to initiate, nor into the quality of the communication process-for example, whether communication about care preferences was started early enough that this could make a material difference to the quality of end-of-life care. Finally, due to the low statistical power for some analyses, particularly in ES, it is possible that the significance of some results is underestimated.

This study shows that initiatives to increase endof-life communication can be ambitious and aim at significant change in clinical practice in a short time. The prerequisites for successful interventions are however still unknown, while challenges to continued high levels of communication between GPs and patients are also apparent. For instance, the ongoing increase in the specialisation of cancer care and palliative care and subsequent task differentiation between healthcare professionals pave the way for new roles and responsibilities in primary and secondary care. This will require better communication between healthcare providers in order to maintain good communication with patients. Future research should provide a broader picture including ACP as a whole as well as including the various healthcare providers.

Conclusion

Broad changes, both increasing and decreasing, were found between 2009 and 2014 in the number of people with cancer with whom certain end-of-life care topics were discussed according to GPs in BE, the NL and ES. Despite international differences that appear to persist over time, end-of-life communication in primary care in Europe can change substantially in a relatively short period of time across patient groups.

Author affiliations

¹Department of Family Medicine and Chronic Care, End-of-Life Care Research Group, Vrije Universiteit Brussel (VUB) & Ghent University, Brussels, Belgium ²Epidemiology, Biostatistics and Prevention Institute, University of Zürich, Zürich, Switzerland

³Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Expertise Center for Palliative Care, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

⁴Epidemiology and Public Health, Health Services Research, Sciensano, Brussels, Belgium

⁵NIVEL Primary Care Database - Sentinel Practices, Netherlands Institute for Health Services Research, Utrecht, The Netherlands

⁶Public Health General Directorate, Regional Ministry of Health (Dirección General de Salud Pública, Consejería de Sanidad), Castile and León, Valladolid, Spain

⁷Department of Public Health and Primary Care, Ghent University, Ghent, Belgium

Acknowledgements The authors wish to acknowledge all participating GP practices for providing the data for this study throughout the years, for which they received no financial incentives.

Contributors All authors contributed equally to the concept of this manuscript. LVdB, LD, BDO-P and TVA designed the EURO SENTIMELC study. SM, GAD and TVA were responsible for organising and monitoring data collection. MNV and YWHP analysed the data. All authors contributed equally to data interpretation. MNV and YWHP drafted the article. All authors critically revised the article and granted approval for publication.

Funding Data collection was funded by the Belgian Scientific Institute of Public Health (now Sciensano), the Netherlands Institute for Health Services Research and the Regional Ministry of Health of Castile and León (Spain). The first author received funding from the European Union's Seventh Framework Programme FP7/2007-2013 (grant agreement no. 602541).

Disclaimer The funding agencies were not involved in the decision to write or submit this manuscript.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval For Belgium, ethics approval was obtained from the Ethical Review Board of Brussels University Hospital of the Vrije Universiteit Brussel (VUB). Formal approval for this research project by a medical ethics committee was not required in the Netherlands according to the Medical Research (Human Subjects) Act (WMO), but permission for the study was sought and obtained from the board of the NIVEL network. The NIVEL Primary Care Database extracts data according to strict guidelines for the privacy protection of patients and GPs. Ethics approval was not required for posthumous collection of anonymous patient data in Spain, according to the legislation of this country.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. Data may be made available on request to the relevant national institute.

ORCID iD

Yolanda W H Penders http://orcid.org/0000-0002-7606-7987

REFERENCES

1 European Commission. Eurostat population database, 2018. Available: https://ec.europa.eu/eurostat/statistics-explained/ index.php/Cancer_statistics [Accessed 4 Dec 2018].

- 2 Etkind SN, Bone AE, Gomes B, *et al*. How many people will need palliative care in 2040? Past trends, future projections and implications for services. *BMC Med* 2017;15.
- 3 Street RL, Mazor KM, Arora NK. Assessing patient-centered communication in cancer care: measures for surveillance of communication outcomes. J Oncol Pract 2016;12:1198–202.
- 4 Dean M, Street RL. *Patient-centered communciation, in textbook of palliative care communication.* Oxford, UK: Oxford University Press, 2015: 238–45.
- 5 Ha JF, Longnecker N. Doctor-patient communication: a review. Ochsner J 2010;10:38–43.
- 6 Epstein AS, Prigerson HG, O'Reilly EM, et al. Discussions of life expectancy and changes in illness understanding in patients with advanced cancer. Int J Clin Oncol 2016;34:2398–403.
- 7 Zolnierek KBH, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. *Med Care* 2009;47:826–34.
- 8 Venetis MK, Robinson JD, Turkiewicz KL, et al. An evidence base for patient-centered cancer care: a metaanalysis of studies of observed communication between cancer specialists and their patients. Patient Educ Couns 2009;77:379–83.
- 9 Greville-Harris M, Dieppe P. Bad is more powerful than good: the nocebo response in medical consultations. *Am J Med* 2015;128:126–9.
- 10 Back AL, Arnold RM, Baile WF, et al. Approaching difficult communication tasks in oncology. CA Cancer J Clin 2005;55:164–77.
- 11 Narang AK, Wright AA, Nicholas LH. Trends in advance care planning in patients with cancer: results from a national longitudinal survey. *JAMA Oncol* 2015;1:601–8.
- 12 Slort W, Schweitzer BPM, Blankenstein AH, *et al.* Perceived barriers and facilitators for general practitioner–patient communication in palliative care: a systematic review. *Palliat Med* 2011;25:613–29.
- 13 Slort W, Blankenstein AH, Deliens L, *et al.* Facilitators and barriers for GP–patient communication in palliative care: a qualitative study among GPs, patients, and end-of-life consultants. *Br J Gen Pract* 2011;61:e167–72.
- 14 Centeno C, Lynch T, Donea O, et al. EAPC atlas of palliative care in Europe 2013 – full edition. Milan, Italy: EAPC (European Association for Palliative Care) Press, 2013.
- 15 The Flemish Cancer League (Vlaamse Liga tegen Kanker, VLK), Think tank affordability of the cancer Treatment. *How can cancer treatment remain affordable? Recommendations for an accessible and sustainable high quality cancer care.* Brussels, Belgium: The Flemish Cancer League, 2013.
- 16 Van Hoof E, Lenaerts L, Remue E. Evaluatie van het Kankerplan [Evaluation of the Belgian Cancer Plan] 2008-2010. Brussels, Belgium: Scientific Institute of Public Health, Cancer Centre, 2012.
- 17 Gysels M, Evans N, Meñaca A, *et al.* On behalf of project PRISMA, culture and end of life care: a scoping exercise in seven European countries. *PLoS One* 2012;7.
- 18 The Economist Intelligence Unit (EIU). The 2015 quality of death index: ranking palliative care across the world, 2015. Available: http://www.economistinsights.com/healthcare/ analysis/quality-death-index-2015 [Accessed 4 Dec 2018].
- 19 Cartwright C, Onwuteaka-Philipsen BD, Williams G, et al. Physician discussions with terminally ill patients: a crossnational comparison. *Palliat Med* 2007;21:295–303.
- 20 Janssens RJ, ten Have HA, Have HAMJten. The concept of palliative care in the Netherlands. *Palliat Med* 2001;15:481–6.
- 21 Van den Block L, Onwuteaka-Philipsen B, Meeussen K, et al. Nationwide continuous monitoring of end-of-life care via representative networks of general practitioners in Europe. BMC Fam Pract 2013;14:73.
- 22 Leemans K, Deliens L, Francke AL, *et al.* Quality indicators for palliative care services: mixed-method study testing for face

validity, feasibility, discriminative power and usefulness. *Palliat Med* 2015;29:71–82.

- 23 Galceran J, Ameijide A, Carulla M, *et al*. Cancer incidence in Spain, 2015. *Clin Transl Oncol* 2017;19:799–825.
- 24 Evans N, Costantini M, Pasman HR, et al. End-of-life communication: a retrospective survey of representative general practitioner networks in four countries. J Pain Symptom Manage 2014;47:604–19.
- 25 Meñaca A, Evans N, Andrew EVW, et al. End-of-life care across southern Europe: a critical review of cultural similarities and differences between Italy, Spain and Portugal. Crit Rev Oncol Hematol 2012;82:387–401.
- 26 Toscani F, Farsides C. Deception, catholicism, and hope: understanding problems in the communication of unfavorable prognoses in traditionally-catholic countries. *Am J Bioeth* 2006;6:W6–18.
- 27 Snyder L, Leffler C. Ethics manual: fifth edition. Ann Intern Med 2005;142:560–82.
- 28 Brinkman-Stoppelenburg A, Rietjens JAC, van der Heide A. The effects of advance care planning on end-of-life care: a systematic review. *Palliat Med* 2014;28:1000–25.
- 29 Lunder U, Červ B, Kodba-Čeh H. Impact of advance care planning on end-of-life management. *Curr Opin Support Palliat Care* 2017;11:293–8.
- 30 Horlait M, Chambaere K, Pardon K, et al. What are the barriers faced by medical oncologists in initiating discussion of palliative care? A qualitative study in Flanders, Belgium. Supportive Care in Cancer 2016;24:3873–81.
- 31 Gysels M, Evans N, Meñaca A, *et al.* Diversity in defining end of life care: an obstacle or the way forward? *PLoS One* 2013;8:e68002.
- 32 Mitchell GK, Burridge LH, Colquist SP, *et al.* General practitioners' perceptions of their role in cancer care and factors which influence this role. *Health Soc Care Community* 2012;20:607–16.
- 33 Wichmann AB, van Dam H, Thoonsen B, *et al.* Advance care planning conversations with palliative patients: looking through the GP's eyes. *BMC Fam Pract* 2018;19:184.

- 34 Davis MP, Temel JS, Balboni T, *et al*. A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. *Ann. Palliat. Med* 2015;4:99–121.
- 35 Ferrell BR, Temel JS, Temin S, *et al.* Integration of palliative care into standard oncology care: American Society of clinical oncology clinical practice guideline update. *J Clin Oncol* 2017;35:96–112.
- 36 Vanbutsele G, Pardon K, Van Belle S, et al. Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial. Lancet Oncol 2018;19:394–404.
- 37 Kain DA, Eisenhauer EA. Early integration of palliative care into standard oncology care: evidence and overcoming barriers to implementation. *Curr. Oncol.* 2016;23:374–7.
- 38 Dutch Ministry of Health, Welfare and Sport (Minister van Volksgezondheid, Welzijn en Sport, VWS). Regeling voorschrijfbevoegdheid van de verpleegkundigen [Official announcement regarding the prescribing powers of nurses], 2015. Available: https://zoek.officielebekendmakingen.nl/stcrt-2015-42244.html [Accessed 4 Dec 2018].
- 39 Vila C, Reñones C, Ferro T, *et al.* Advanced breast cancer clinical nursing curriculum: review and recommendations. *Clin Transl Oncol* 2017;19:251–60.
- 40 Sussman J, Howell D, Bainbridge D, et al. The impact of specialized oncology nursing on patient supportive care outcomes. J Psychosoc Oncol 2011;29:286–307.
- 41 Eelen S, Bauwens S, Baillon C, *et al.* The prevalence of burnout among oncology professionals: oncologists are at risk of developing burnout. *Psychooncology* 2014;23:1415–22.
- 42 Teno JM. Measuring end-of-life care outcomes retrospectively. *J Palliat Med* 2005;8:S42–9.
- 43 Fried TR, Bradley EH, O'Leary J. Prognosis communication in serious illness: perceptions of older patients, caregivers, and clinicians. J Am Geriatr Soc 2003;51:1398–403.